基本信息
浏览量:394
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
个人简介
He has published more than 418 scientific papers, edited four books, and holds 56 patents and patent applications.
In addition to his academic research, Professor Suslick has had significant entrepreneurial experience. He was the lead consultant for Molecular Biosystems Inc. and part of the team that commercialized the first echo contrast agent for medical sonography, Albunex™, which became Optison™ by GE Healthcare. In addition, he was the founding consultant for VivoRx Pharmaceuticals and helped invent and commercialize Abraxane™, albumin microspheres with a paclitaxel core, which is the predominant current delivery system for taxol chemotherapy for breast cancer; VivoRx became Abraxis Bioscience, which was acquired by Celgene for $2.9 billion. Most recently, Suslick invented, developed, and commercialized the "optoelectronic nose", a simple but highly effective technology for the identification and quantification of gas analytes. This has found important applications in the detection of toxic gases and explosives, the discrimination among complex odorants, and rapid diagnosis of disease based on their smell. He then co-founded ChemSensing, which began the commercialization of the Suslick group's optoelectronic nose technology and its successor, iSense Systems and Specific Diagnostics (both in Silicon Valley), for the biomedical applications of this unique sensor technology.
In addition to his academic research, Professor Suslick has had significant entrepreneurial experience. He was the lead consultant for Molecular Biosystems Inc. and part of the team that commercialized the first echo contrast agent for medical sonography, Albunex™, which became Optison™ by GE Healthcare. In addition, he was the founding consultant for VivoRx Pharmaceuticals and helped invent and commercialize Abraxane™, albumin microspheres with a paclitaxel core, which is the predominant current delivery system for taxol chemotherapy for breast cancer; VivoRx became Abraxis Bioscience, which was acquired by Celgene for $2.9 billion. Most recently, Suslick invented, developed, and commercialized the "optoelectronic nose", a simple but highly effective technology for the identification and quantification of gas analytes. This has found important applications in the detection of toxic gases and explosives, the discrimination among complex odorants, and rapid diagnosis of disease based on their smell. He then co-founded ChemSensing, which began the commercialization of the Suslick group's optoelectronic nose technology and its successor, iSense Systems and Specific Diagnostics (both in Silicon Valley), for the biomedical applications of this unique sensor technology.
研究兴趣
论文共 697 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Johanna K. Hettinga,Brian Lyons,Joel Balkaran,Pramila Rijal, Darcy Dunn-Lawless,Lisa Caproni,Michael Gray,Kenneth S. Suslick,Constantin C. Coussios,Robert C. Carlisle
ADVANCED THERAPEUTICS (2023)
ANALYSIS & SENSINGno. 2 (2023)
The Journal of the Acoustical Society of Americano. 4 (2022)
SHOCK COMPRESSION OF CONDENSED MATTER - 2019no. 1 (2020)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn